Halo Healthcare Inc.
Early detection of breast cancer
This article was originally published in Start Up
A women’s health care company in turnaround – one well recognized for assessing a woman’s risk of developing breast cancer through the HALO breast test – is developing a breast cancer diagnostic based on the presence of three protein biomarkers found in breast nipple aspirate fluid. The HALO Pivot diagnostic kit from Halo Healthcare Inc. is an in-office, noninvasive test for diagnosing cancer or a recurrence at a very early stage.
You may also be interested in...
Clinical Trial Diversity Planning Requires Prevalence-Based Enrollment Goals, Metrics For Gauging Success
Academic and industry experts caution against relying on historical enrollment numbers when setting new targets for under-represented populations and tout real-time monitoring dashboards, as well as a role for data monitoring committees, in assessing whether targets are being met in ongoing studies.
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.
Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.